Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
ContraVir to Present at Two Upcoming Investor Conferences
PR Newswire - Wed Sep 03, 3:42PM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, to be held September 8-10, 2014, in New York City, and the Aegis Capital 2014 Healthcare and Technology Conference, to be held September 10-13, 2014 in Las Vegas.
ContraVir Appoints Industry Veteran William Hornung as Its Chief Financial Officer
Business Wire - Tue Jul 08, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that William Hornung has joined the Company as its Chief Financial Officer. Mr. Hornung has over 22 years of finance and operations leadership experience in the biopharmaceutical industry with companies such as PTC Therapeutics (NASDAQ
Baxter International to Split into Two Businesses; Spherix Sues Cisco over 11 Patent Infringements
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Baxter International Inc. (NYSE: BAX) - For an in-depth report on Baxter International Inc. follow: www.BullTrends.com/stockquote/BAX
ContraVir Appoints James Sapirstein as Chief Executive Officer and Board Member
Business Wire - Thu Mar 20, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development of antiviral technologies, today announced the appointment of James Sapirstein as Chief Executive Officer, and a member of the ContraVir Board of Directors. Mr. Sapirstein will lead the Company's strategic growth plan for the future, and, in particular, the clinical development of FV-100 to treat shingles (herpes zoster) patients.